Nurix Therapeutics, Inc. NRIX Balance Sheet Statement
| Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | ||
|---|---|---|---|---|---|---|
| $72.16M-6.1% | $247.93M+124% | $79.41M-20.6% | $85.16M-27.6% | $76.82M+51.5% | ||
| $554.39M-1.7% | $606.82M-2.0% | $440.6M-3.4% | $515.33M+14.5% | $563.7M+125% | ||
| $21.7M+17.6% | $22.49M+26.7% | $20.5M+20.1% | $18.77M+1.2% | $18.45M+3.2% | ||
| $636.13M+3.4% | $688.14M+2.8% | $522.47M+1.7% | $591.56M+15.8% | $615.04M+96.7% | ||
| $10.29M+22.6% | $11.22M-2.3% | $8.61M+120% | $5.95M+112% | $8.4M+41.9% | ||
| $18.75M-38.7% | $17.58M-54.2% | $25.99M-45.8% | $27.42M-41.4% | $30.59M-33.6% | ||
| $92.2M+2.5% | $86.47M-9.8% | $82.35M-4.6% | $75.61M-6.4% | $89.99M+2.7% | ||
| $155.24M+15.7% | $149.39M+4.9% | $150.22M+9.9% | $143.95M+2.6% | $134.13M-6.8% | ||
| 500M0.0% | 500M0.0% | 500M0.0% | 500M0.0% | 500M0.0% | ||
| -$1.09B-37.1% | -$1B-35.8% | -$925.01M-36.0% | -$838.58M-32.8% | -$795.12M-35.5% | ||
| $480.89M0.0% | $538.75M+2.2% | $372.25M-1.2% | $447.6M+20.7% | $480.92M+185% | ||
| $636.13M+3.4% | $688.14M+2.8% | $522.47M+1.7% | $591.56M+15.8% | $615.04M+96.7% |
Chart any of these lines over time, or line them up against competitors.
Compare these in charts →Questions, answered.
- What are Nurix Therapeutics, Inc.'s total assets?
- Nurix Therapeutics, Inc. (NRIX) holds $636.1M in total assets, up 3.4% year over year.
- How much debt does Nurix Therapeutics, Inc. have?
- Nurix Therapeutics, Inc. carries $58.7M in total debt against $480.9M of shareholders' equity, a debt-to-equity ratio of 0.12.
- How much cash does Nurix Therapeutics, Inc. have?
- Nurix Therapeutics, Inc. holds $72.2M in cash and equivalents.
- Can Nurix Therapeutics, Inc. cover its short-term obligations?
- Its current ratio is 6.01 — current assets exceed current liabilities.
- Where does Nurix Therapeutics, Inc.'s balance sheet data come from?
- Every line is extracted from Nurix Therapeutics, Inc.'s SEC filings (10-K and 10-Q) and tagged in XBRL. Switch between quarterly, annual, and trailing-twelve-month views, or open any line for its full history and peer comparisons.
